Pacira BioSciences, Inc. (PCRX)
Who owns Pacira BioSciences, Inc. (PCRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 85.7% of the shares are freely tradable; institutional investors hold 115.4%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 17.12 | 6,735,343 | -4.7 | 03/31/2026 |
| Vanguard Group Inc | 12.23 | 4,812,955 | -7.4 | 12/31/2025 |
| Doma Perpetual Capital Management LLC | 7.06 | 2,777,794 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 6.36 | 2,501,286 | +0.0 | 03/31/2026 |
| Dimensional Fund Advisors, Inc. | 5.24 | 2,060,597 | +5.7 | 03/31/2026 |
| D. E. Shaw & Co LP | 5.04 | 1,982,724 | -2.8 | 03/31/2026 |
| State Street Corp | 4.88 | 1,919,610 | +1.9 | 03/31/2026 |
| Renaissance Technologies Corp | 4.64 | 1,825,501 | -3.1 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.53 | 1,784,049 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 6.34 | 2,493,038 | +0.0 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 23. Apr 2026 | Shawn Cross | CFO | Sell | 12,941 | 25.16 | 325,596 |
| 22. Apr 2026 | Shawn Cross | CFO | Sell | 1,500 | 25.01 | 37,515 |
| 21. Apr 2026 | Shawn Cross | CFO | Sell | 2,845 | 25.01 | 71,153 |
| 20. Apr 2026 | Shawn Cross | CFO | Sell | 7,714 | 25.14 | 193,930 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.